Vanguard Portfolio Management’s Ginkgo Bioworks DNA Stock Holding History
Bought
Maintained
Sold
Other funds holding DNA
Vanguard Portfolio Management's DNA Position: Q3 2026 in Review
Vanguard Portfolio Management increased its Ginkgo Bioworks (DNA) stake by 55% in Q3 2026, buying an estimated $4.23M and bringing the position to 1,457,573 shares worth $18.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1975.
Vanguard Portfolio Management first reported a position in DNA in Q1 2026 and has held it in 3 quarters since. 185 funds tracked by Wall St. Rank hold DNA as of Q3 2026.
- Vanguard Portfolio Management held 1,457,573 shares of Ginkgo Bioworks worth $18.7M as of Q3 2026.
- Vanguard Portfolio Management bought 519,770 Ginkgo Bioworks shares in Q3 2026, an estimated $4.23M.
- Ginkgo Bioworks made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #1975 holding.
- Vanguard Portfolio Management first reported a position in Ginkgo Bioworks in Q1 2026 and has held it in 3 quarters since.
- 185 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2026.
Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.